Joshua J Skydel, Reshma Ramachandran, Sakinah Suttiratana, Joseph S Ross, Christopher M Burns, Joshua D Wallach
{"title":"美国系统性红斑狼疮治疗方法行业赞助临床试验的地域和人口代表性。","authors":"Joshua J Skydel, Reshma Ramachandran, Sakinah Suttiratana, Joseph S Ross, Christopher M Burns, Joshua D Wallach","doi":"10.3899/jrheum.2023-0920","DOIUrl":null,"url":null,"abstract":"Clinical research into potential therapies for systemic lupus erythematosus (SLE) has increased over the last 2 decades, driven by the discovery of new targetable pathways, yet uncertainty persists over which patients benefit from new therapies.<sup>1</sup> Black patients and other minoritized populations, which disproportionately experience severe disease, are underrepresented in SLE trials.<sup>2</sup>.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"8 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Geographic and Demographic Representation in Industry-Sponsored, US-Based Clinical Trials of Systemic Lupus Erythematosus Therapies.\",\"authors\":\"Joshua J Skydel, Reshma Ramachandran, Sakinah Suttiratana, Joseph S Ross, Christopher M Burns, Joshua D Wallach\",\"doi\":\"10.3899/jrheum.2023-0920\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Clinical research into potential therapies for systemic lupus erythematosus (SLE) has increased over the last 2 decades, driven by the discovery of new targetable pathways, yet uncertainty persists over which patients benefit from new therapies.<sup>1</sup> Black patients and other minoritized populations, which disproportionately experience severe disease, are underrepresented in SLE trials.<sup>2</sup>.\",\"PeriodicalId\":501812,\"journal\":{\"name\":\"The Journal of Rheumatology\",\"volume\":\"8 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-12-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Journal of Rheumatology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3899/jrheum.2023-0920\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of Rheumatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3899/jrheum.2023-0920","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Geographic and Demographic Representation in Industry-Sponsored, US-Based Clinical Trials of Systemic Lupus Erythematosus Therapies.
Clinical research into potential therapies for systemic lupus erythematosus (SLE) has increased over the last 2 decades, driven by the discovery of new targetable pathways, yet uncertainty persists over which patients benefit from new therapies.1 Black patients and other minoritized populations, which disproportionately experience severe disease, are underrepresented in SLE trials.2.